Undisclosed 505(b)(2) Programs

About Nanocopoeia

Nanocopoeia is a U.S.-based drug delivery company founded in 2004, originating from a University of Minnesota technology license. It has evolved from a medical device coating services model to a pharmaceutical development company focused on enhancing the performance of low-solubility drugs through its nanoparticle engineering platform. With substantial investor backing, the company has built a technically accomplished team to create valuable 505(b)(2) opportunities via co-development and out-licensing partnerships. Its core value proposition lies in improving bioavailability and reducing product defects to address significant unmet needs in drug formulation.